0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-33

IL-33

Brief Information

Name:Interleukin-33
Target Synonym:Nuclear Factor For High Endothelial Venules,DVS27-Related Protein,IL1F11,IL33,Interleukin-1 family member 11,IL-1F11,Interleukin 33,Nuclear Factor From High Endothelial Venules,C9orf26,NF-HEV,Chromosome 9 Open Reading Frame 26 (NF-HEV),Interleukin-1 Famil
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

IL3-C5245-ELISA
Cynomolgus IL-33, His TagCynomolgus IL-33, His Tag (Cat. No. IL3-C5245) ELISA bioactivity

Immobilized Cynomolgus IL-33, His Tag (Cat. No. IL3-C5245) at 5 μg/mL (100 μL/well) can bind Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) with a linear range of 2-78 ng/mL (QC tested).

IL3-H82H5-MALS-HPLC
Biotinylated Human IL-33, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human IL-33, His,Avitag(Cat. No. IL3-H82H5) was more than 90% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human IL-33, His,AvitagBiotinylated Human IL-33, His,Avitag (Cat. No. IL3-H82H5) ELISA bioactivity

Immobilized Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-33, His,Avitag (Cat. No. IL3-H82H5) with a linear range of 0.01-0.156 μg/mL (QC tested).

Customer Reviews

Synonym Name

IL33,DV27,C9ORF26,IL1F11,NFHEV,DKFZp586H0523,DVS27,NFEHEV,RP11-575C20.2

Background

Interleukin 33 (IL33) is known as C9orf26, DKFZp586H0523, DVS27, NF-HEV, NFEHEV, RP11-575C20.2,and is a cytokine belonging to the IL-1 superfamily. IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. IL-33 mediates its biological effects by interacting with the receptors ST2 (aka IL1RL1) and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LY-3375880 LY-3375880 Phase 2 Clinical Eli Lilly And Company Dermatitis, Atopic Details
Etokimab ANB-020 Phase 2 Clinical Anaptysbio Pulmonary Eosinophilia; Sinusitis; Asthma; Peanut Hypersensitivity; Dermatitis, Atopic; Hypersensitivity Details
PF-06817024 PF-06817024 Phase 1 Clinical Pfizer Inc Nose Diseases; Sinusitis; Dermatitis, Atopic Details
MT-2990 MT-2990 Phase 2 Clinical Mitsubishi Tanabe Pharma Corp Rhinitis, Allergic, Seasonal; Pain; Autoimmune Diseases; Inflammation Details
Anti-IL-33 mAb (Regeneron Pharmaceuticals/Sanofi) REGN-3500; SAR-440340 Phase 3 Clinical Regeneron Pharmaceuticals Inc, Sanofi Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details

This web search service is supported by Google Inc.

totop